Stock
Can-Fite BioPharma Ltd. American Depositary Shares, each representing two (2) CANF
Overview
CANF market data
Price History
CANF price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$5.97 Diluted earnings per share over the trailing twelve months.
- Beta
- -0.48 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- -2,422.4% Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $374.00 – $9,000,000.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $22.7M · P/B 4.68 · P/S 12.46.
Company News
Can-Fite BioPharma Submits Phase 2 Clinical Study Protocol To Bambino Gesù Children's Hospital In Rome, Italy, For First Clinical Evaluation Of Piclidenoson In Patients With Lowe SyndromeBenzinga · Aug 3, 2026, 11:03 AM
Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in OncologyGlobenewswire Inc · Jul 20, 2026, 12:02 PM
Can-Fite Pancreatic Cancer Data Accepted For ESMO Presentation, To Present Namodenoson Cancer Study Results At The EventBenzinga · Jul 20, 2026, 11:16 AM
Can-Fite BioPharma Completes Enrolment Of First 247 Patients In Pivotal Phase 3 Study Evaluating Piclidenoson For Treatment Of Moderate-To-Severe Plaque PsoriasisBenzinga · Jul 6, 2026, 11:10 AM
HC Wainwright & Co. Reiterates Buy on Can Fite Biopharma, Raises Price Target to $8Benzinga · Jul 2, 2026, 11:05 AM
Can-Fite Highlights Survival Outcomes In Pancreatic Cancer PatientsBenzinga · Jul 1, 2026, 2:15 PM
Market-Moving News for July 1stBenzinga · Jul 1, 2026, 11:25 AM
CanFite Reported Namodenoson In Predominantly Third-Line Pancreatic Cancer Patients Demonstrated Durable Survival Despite Advanced Disease; Second-Line Patient Remains Alive More Than 18 MonthsBenzinga · Jul 1, 2026, 11:10 AM
Can-Fite Stock Jumps After Japan Patent Boosts Obesity Drug CaseBenzinga · Jun 26, 2026, 2:15 PM
Market-Moving News for June 26thBenzinga · Jun 26, 2026, 11:30 AM